Rodman & Renshaw
R&R helps biotech companies raise capital through private placements and other sophisticated transactions. It's a big market, with 1,100 private and 330 publicly traded companies in the space. And with the average drug requiring $1.2 billion to reach the market, biotechs often feed at Wall Street's trough.
For the most part, R&R has done quite well, capitalizing on the market opportunity. For the first six months of 2007, revenue spiked 75% to $47.2 million. The company even posted a profit of $10 million. So why is Wall Street lukewarm on R&R's public offering?
First of all, R&R gets an average 75% of its revenue from life sciences, which can be a volatile sector. If a few deals slip away, the growth rate could dampen considerably.
At the same time, R&R must compete with rivals such as Bank of America Securities
No doubt, R&R realizes it needs to diversify its business, which should be easier with the boost from the public offering. However, it's not an easy transition to make, and is yet another thing for Wall Street to worry about.
For more Foolishness:
Fool contributor Tom Taulli, author of The Complete M&A Handbook, does not own shares mentioned in this article. He is currently ranked 5,221 out of more than 65,000 Motley Fool CAPS players. Bank of America is an Income Investor recommendation. The Fool has a disclosure policy.